Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | P4HB | P07237 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30444713 | 1.00 | MRGPRX4 (0.56) | MRGPRX4GSK3BCYP11B1CYP11B2PLAU | |
| SCHEMBL6831985 | 0.94 | CYP11B1 (0.52) | MRGPRX4GSK3BCYP11B1CYP11B2PLAU | |
| SCHEMBL6578619 | 0.94 | CYP11B1 (0.55) | MRGPRX4GSK3BCYP11B1CYP11B2PLAU | |
| SCHEMBL7822720 | 0.90 | PLAU (0.61) | MRGPRX4GSK3BCYP11B1CYP11B2PLAU | |
| SCHEMBL3456924 | 0.89 | MRGPRX4 (0.52) | MRGPRX4GSK3BCYP11B1CYP11B2PLAU | |
| SCHEMBL5928256 | 0.88 | RAB9A (0.52) | MRGPRX4CYP11B1CYP11B2PLAUTSHR | |
| SCHEMBL19203281 | 0.87 | GSK3B (0.54) | MRGPRX4GSK3BCYP11B1CYP11B2PLAU | |
| SCHEMBL7650287 | 0.85 | GSK3B (0.59) | MRGPRX4GSK3BGRM5P4HB | |
| SCHEMBL5652160 | 0.85 | GSK3B (0.59) | MRGPRX4GSK3BGRM5P4HB | |
| SCHEMBL1800821 | 0.84 | TSHR (0.53) | TSHRLOXL2CYP4F2CYP4A11POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 496 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120020114-A | Preparation method of N-alkenyl amide compound | 中国石油化工股份有限公司 | 2025-05-20 | — | — | CN | claimed |
| CN-120020115-A | Process for the preparation of N- (alkyl-2-hydroxy) alkylamides and N-alkenylamides | 中国石油化工股份有限公司 | 2025-05-20 | — | — | CN | claimed |
| CN-114920736-B | Quinoline ring-containing 1,2, 4-oxadiazole substituted benzamide compound and preparation method and application thereof | 浙江工业大学 | 2024-01-30 | — | — | CN | claimed |
| CN-112979627-B | Pyrazole bi-1, 2, 4-oxadiazole substituted benzamide compound and preparation method and application thereof | 浙江工业大学 | 2023-08-22 | — | — | CN | claimed |
| CN-115286622-A | Quinoline ring-containing 1,2, 4-oxadiazole substituted benzamide compound and preparation method and application thereof | 浙江工业大学 | 2022-11-04 | — | — | CN | claimed |
| CN-115260175-A | 5- (pyrazole-5-yl) -1,2,4-oxadiazole substituted benzamide compound and preparation method and application thereof | 浙江工业大学 | 2022-11-01 | — | — | CN | claimed |
| CN-114920734-A | 5- (pyrazole-5-yl) -1,2, 4-oxadiazole substituted benzamide compounds and preparation method and application thereof | 浙江工业大学 | 2022-08-19 | — | — | CN | claimed |
| CN-114920736-A | Quinoline ring-containing 1,2, 4-oxadiazole-substituted benzamide compound and preparation method and application thereof | 浙江工业大学 | 2022-08-19 | — | — | CN | claimed |
| CN-114805120-A | Synthesis process of m-cyanomethyl benzoate | 江苏瑞达环保科技有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114480225-B | Method for biologically and intensively treating high-salt chemical wastewater | 江苏聚庚科技有限公司 | 2022-06-17 | — | — | CN | claimed |
| CN-114480225-A | Method for biologically and intensively treating high-salt chemical wastewater | 江苏聚庚科技有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-112979627-A | Pyrazole bi-1, 2, 4-oxadiazole substituted benzamide compounds and preparation method and application thereof | 浙江工业大学 | 2021-06-18 | — | — | CN | claimed |
| CN-112707831-A | Synthetic method of 3- (1-aminocyclopropyl) methyl benzoate | 阿里生物新材料（常州）有限公司 | 2021-04-27 | — | — | CN | claimed |
| CN-111675631-A | Synthesis process of cyano ketoprofen | 湖北仙盛科技股份有限公司 | 2020-09-18 | — | — | CN | claimed |
| CN-111675672-A | Method for preparing astallurens | 石家庄市度智医药科技有限公司 | 2020-09-18 | — | — | CN | claimed |
| CN-104292180-A | Preparation method of oxadiazole derivative | Hunan huateng pharmaceutical co ltd | 2015-01-21 | — | — | CN | claimed |
| CN-101891649-B | Novel 3-cyano methyl benzoate preparing method | JINGZHOU TENGFEI CHEMICALS CO LTD | 2013-05-08 | — | — | CN | claimed |
| CN-101891649-A | Novel 3-cyano methyl benzoate preparing method | JINGZHOU TENGFEI CHEMICALS CO LTD | 2010-11-24 | — | — | CN | claimed |
| US-20100121070-A1 | METHODS FOR THE SYNTHESIS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS, INC. | 2010-05-13 | — | — | US | claimed |
| CN-118005534-B | Preparation method of 3-cyanobenzoic acid | 安顺学院 | 2026-05-19 | — | — | CN | disclosed |
| WO-2025243250-A1 | A PROCESS FOR THE PREPARATION OF 3-[5-(2-FLUOROPHENYL)-1,2,4-OXADIAZOL-3-YL]BENZOIC ACID | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2025-11-27 | — | — | WO | disclosed |
| EP-4610260-A1 | ARYL HETEROCYCLIC KV1.3 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Shenshi Wise Technology Co., Ltd. (CN) | 2025-09-03 | — | — | EP | disclosed |
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-06-05 | — | — | US | disclosed |
| CN-120020115-A | Process for the preparation of N- (alkyl-2-hydroxy) alkylamides and N-alkenylamides | 中国石油化工股份有限公司 | 2025-05-20 | — | — | CN | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20250101013-A1 | FUNCTIONALIZED AMINOTHIAZOLES | LEADXPRO AG (CH) | 2025-03-27 | — | — | US | disclosed |
| CN-115141120-B | Electro-oxidation preparation method of atta Lu Lun | 湖南大学 | 2025-03-21 | — | — | CN | disclosed |
| WO-2025059469-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS AKT INHIBITORS | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-119638642-A | Bicyclic compounds, pharmaceutical composition and application thereof | 暨南大学 | 2025-03-18 | — | — | CN | disclosed |
| CN-119390668-A | Compound with ketoxime ether structure and application thereof | 复旦大学 | 2025-02-07 | — | — | CN | disclosed |
| CN-119241504-A | Spiroindoline inhibitors of KIF18A | 沃拉斯查疗法公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-4466267-A1 | FUNCTIONALIZED AMINOTHIAZOLES | LeadXpro AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| EP-4025573-B9 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2024-11-20 | — | — | EP | disclosed |
| CN-116041277-B | Phenyl and biphenyl substituted five-membered heterocyclic compound, preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2024-11-01 | — | — | CN | disclosed |
| EP-4452918-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240351984-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | US | disclosed |
| CN-118703011-A | Blue phosphor film material of benzene derivative with polyacrylic acid as matrix, and preparation method and application thereof | 辽宁大学 | 2024-09-27 | — | — | CN | disclosed |
| US-12084420-B2 | Indoline compounds for inhibiting KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| CN-118574828-A | Functionalized aminothiazoles | 里德埃克斯普洛股份公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-4025573-B1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2024-07-24 | — | — | EP | disclosed |
| EP-4392407-A1 | SPIRO INDOLINE INHIBITORS OF KIF18A | Volastra Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-114920667-B | Electrochemical preparation method of atta Lu Lunzhi | 湖南大学 | 2024-06-21 | — | — | CN | disclosed |
| CN-118103352-A | Spiroindoline inhibitors of KIF18A | 沃拉斯查疗法公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118026930-A | Isoquinoline derivative and synthesis method thereof | 湖南师范大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-118026948-A | Tri-aromatic ring compound and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-118005534-A | Preparation method of 3-cyanobenzoic acid | 安顺学院 | 2024-05-10 | — | — | CN | disclosed |
| WO-2024088343-A1 | ARYL HETEROCYCLIC KV1.3 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2024-05-02 | — | — | WO | disclosed |
| CN-117946111-A | Aryl heterocycle Kv1.3 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-04-30 | — | — | CN | disclosed |
| US-11958833-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-16 | — | — | US | disclosed |
| CN-114341133-B | Substituted cyanopyrrolidines having USP30 inhibitor activity | 特殊治疗有限公司 | 2024-02-27 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| CN-114656461-B | Quinoline ring-containing 1,2, 4-oxadiazole substituted benzamide compound and synthetic method and application thereof | 浙江工业大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-114920736-B | Quinoline ring-containing 1,2, 4-oxadiazole substituted benzamide compound and preparation method and application thereof | 浙江工业大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-112979627-B | Pyrazole bi-1, 2, 4-oxadiazole substituted benzamide compound and preparation method and application thereof | 浙江工业大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-112979627-B | Pyrazole bi-1, 2, 4-oxadiazole substituted benzamide compound and preparation method and application thereof | 浙江工业大学 | 2023-08-22 | — | — | CN | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| EP-4101846-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023139132-A1 | FUNCTIONALIZED AMINOTHIAZOLES | LEADXPRO AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| US-20230218587-A1 | COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-13 | — | — | US | disclosed |
| WO-2023122276-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| CN-116041277-A | Phenyl and biphenyl substituted five-membered heterocyclic compound, preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2023-05-02 | — | — | CN | disclosed |
| WO-2023028564-A1 | SPIRO INDOLINE INHIBITORS OF KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-112955448-B | Aromatic ring or aromatic heterocyclic compound and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-4122929-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-4122929-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-4101846-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11497736-B2 | Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| CN-115286622-A | Quinoline ring-containing 1,2, 4-oxadiazole substituted benzamide compound and preparation method and application thereof | 浙江工业大学 | 2022-11-04 | — | — | CN | disclosed |
| CN-115260175-A | 5- (pyrazole-5-yl) -1,2,4-oxadiazole substituted benzamide compound and preparation method and application thereof | 浙江工业大学 | 2022-11-01 | — | — | CN | disclosed |
| EP-3377476-B1 | HYDROGEN ISOTOPE-ENRICHED ANALOGUES OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF | PTC THERAPEUTICS INC (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20220315572-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| CN-115141120-A | Electrooxidation preparation method of astallurens | 湖南大学 | 2022-10-04 | — | — | CN | disclosed |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3390391-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2022-09-14 | — | — | EP | disclosed |
| CN-109071468-B | Heterocyclic compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114920734-A | 5- (pyrazole-5-yl) -1,2, 4-oxadiazole substituted benzamide compounds and preparation method and application thereof | 浙江工业大学 | 2022-08-19 | — | — | CN | disclosed |
| CN-114920736-A | Quinoline ring-containing 1,2, 4-oxadiazole-substituted benzamide compound and preparation method and application thereof | 浙江工业大学 | 2022-08-19 | — | — | CN | disclosed |
| CN-114920667-A | Electrochemical preparation method of astraglucol | 湖南大学 | 2022-08-19 | — | — | CN | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| CN-114805120-A | Synthesis process of m-cyanomethyl benzoate | 江苏瑞达环保科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-114805120-A | Synthesis process of m-cyanomethyl benzoate | 江苏瑞达环保科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-108929263-B | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-07-22 | — | — | CN | disclosed |
| WO-2022155419-A1 | INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. (US) | 2022-07-21 | — | — | WO | disclosed |
| EP-4025573-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-07-13 | — | — | EP | disclosed |
| CN-114656461-A | Quinoline ring-containing 1,2, 4-oxadiazole-substituted benzamide compound and synthetic method and application thereof | 浙江工业大学 | 2022-06-24 | — | — | CN | disclosed |
| CN-114480225-B | Method for biologically and intensively treating high-salt chemical wastewater | 江苏聚庚科技有限公司 | 2022-06-17 | — | — | CN | disclosed |
| EP-3889142-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2022-06-15 | — | — | EP | disclosed |
| CN-114480225-A | Method for biologically and intensively treating high-salt chemical wastewater | 江苏聚庚科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220127258-A1 | AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd. (CN) | 2022-04-28 | — | — | US | disclosed |
| CN-114341133-A | Substituted cyanopyrrolidines with USP30 inhibitor activity | 特殊治疗有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114269340-A | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2022015977-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| EP-3277675-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210380562-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210380562-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| EP-3919489-A1 | AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd (CN) | 2021-12-08 | — | — | EP | disclosed |
| EP-3889142-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11130748-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-28 | — | — | US | disclosed |
| US-11130748-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-28 | — | — | US | disclosed |
| EP-3632902-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| CN-108368089-B | Deubiquitinase inhibitor | 特殊治疗有限公司 | 2021-07-06 | — | — | CN | disclosed |
| CN-112979627-A | Pyrazole bi-1, 2, 4-oxadiazole substituted benzamide compounds and preparation method and application thereof | 浙江工业大学 | 2021-06-18 | — | — | CN | disclosed |
| US-11034690-B2 | Heterocyclic modulators of lipid synthesis | Saginiet Biosciences Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| CN-112955448-A | Aromatic ring or aromatic heterocyclic compound and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-3549936-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3190108-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-112707831-A | Synthetic method of 3- (1-aminocyclopropyl) methyl benzoate | 阿里生物新材料（常州）有限公司 | 2021-04-27 | — | — | CN | disclosed |
| CN-107207445-B | Adenosine A3Modulators of receptors | 帕罗生物制药有限公司 | 2021-03-16 | — | — | CN | disclosed |
| WO-2021043870-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021043870-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2021-03-11 | — | — | WO | disclosed |
| US-20210038572-A1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC THERAPEUTICS, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10849885-B2 | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy | PTC THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| CN-111825654-A | Phenylmethylene piperidine derivatives, preparation method, intermediates and uses thereof | 北京酷瓴生物技术有限公司 | 2020-10-27 | — | — | CN | disclosed |
| WO-2020211836-A1 | BENZENE PIPERIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF | 北京酷瓴生物技术有限公司 | 2020-10-22 | — | — | WO | disclosed |
| CN-111777528-A | Preparation method of m-cyanomethyl benzoate | 湖北仙盛科技股份有限公司 | 2020-10-16 | — | — | CN | disclosed |
| CN-111675631-A | Synthesis process of cyano ketoprofen | 湖北仙盛科技股份有限公司 | 2020-09-18 | — | — | CN | disclosed |
| CN-111675672-A | Method for preparing astallurens | 石家庄市度智医药科技有限公司 | 2020-09-18 | — | — | CN | disclosed |
| CN-111675672-A | Method for preparing astallurens | 石家庄市度智医药科技有限公司 | 2020-09-18 | — | — | CN | disclosed |
| US-20200261425-A1 | COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-10675272-B2 | Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200172516-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-20200172516-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| CN-111108092-A | Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-05-05 | — | — | CN | disclosed |
| EP-3632902-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | LYCERA CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | LYCERA CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190308969-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2019-10-10 | — | — | US | disclosed |
| EP-3549936-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2019-09-12 | — | — | US | disclosed |
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2019-09-12 | — | — | US | disclosed |
| US-20190269694-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2019-09-05 | — | — | US | disclosed |
| US-20190224173-A1 | COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2019-07-25 | — | — | US | disclosed |
| EP-3248964-B1 | THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS | PALOBIOFARMA SL (ES) | 2019-07-17 | — | — | EP | disclosed |
| EP-3504204-A1 | INDAZOLYL-L,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | Lycera Corporation (US) | 2019-07-03 | — | — | EP | disclosed |
| US-10285980-B2 | Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3472137-A1 | PROCESS FOR PREPARING ATALUREN AND ITS INTERMEDIATES | ScinoPharm Taiwan, Ltd. (TW) | 2019-04-24 | — | — | EP | disclosed |
| US-20190099405-A1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC THERAPEUTICS, INC. | 2019-04-04 | — | — | US | disclosed |
| US-10238637-B2 | Modulators of the adenosine A3 receptors | PALOBIOFARMA, S.L. (ES) | 2019-03-26 | — | — | US | disclosed |
| CN-106316885-B | A kind of preparation method of 3- [5- (2- fluorophenyl) -1,2,4- oxadiazoles -3- base] benzoic acid | 普济生物科技（台州）有限公司 | 2019-02-12 | — | — | CN | disclosed |
| US-10189822-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10172836-B2 | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation supression therapy | PTC THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| CN-109071468-A | Heterocyclic compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-108929263-A | Aryl amide Kv2.1 inhibitor and preparation method thereof, pharmaceutical composition and purposes | 中国医学科学院药物研究所 | 2018-12-04 | — | — | CN | disclosed |
| US-10138215-B2 | Process for preparing ataluren and its intermediates | SCINOPHARM TAIWAN, LTD. (TW) | 2018-11-27 | — | — | US | disclosed |
| US-20180311219-A1 | COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2018-11-01 | — | — | US | disclosed |
| EP-3390391-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2018-10-24 | — | — | EP | disclosed |
| US-20180263963-A1 | MODULATORS OF THE ADENOSINE A3 RECEPTORS | PALOBIOFARMA, S.L. (ES) | 2018-09-20 | — | — | US | disclosed |
| US-10071081-B2 | Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use | PTC THERAPEUTICS, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| CN-108368089-A | Novel Compounds | 特殊治疗有限公司 | 2018-08-03 | — | — | CN | disclosed |
| US-10034863-B2 | Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| WO-2018133730-A1 | HETEROCYCLIC COMPOUND, PREPARATION METHOD AND USE THEREFOR | 四川科伦博泰生物医药股份有限公司 | 2018-07-26 | — | — | WO | disclosed |
| EP-2250165-B1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2018-07-25 | — | — | EP | disclosed |
| EP-2402002-B1 | Compositions comprising an 1,2,4-oxadiazole and uses thereof for treating diseases associated with a premature stop codon | PTC THERAPEUTICS INC (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-3345895-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-3103800-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20180140583-A1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC THERAPEUTICS, INC. | 2018-05-24 | — | — | US | disclosed |
| CN-105461650-B | Solvate of Yi Zhong oxadiazole compounds and preparation method thereof | 杭州普晒医药科技有限公司 | 2018-04-13 | — | — | CN | disclosed |
| US-20180092887-A1 | COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. | 2018-04-05 | — | — | US | disclosed |
| US-20180079746-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2018-03-22 | — | — | US | disclosed |
| WO-2018039539-A1 | INDAZOLYL-L,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2018-03-01 | — | — | WO | disclosed |
| US-9877952-B2 | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy | PTC THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9861617-B2 | Compositions of 1,2,4-oxadiazole benzoic acid compounds and methods for their use | PTC THERAPEUTICS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| WO-2017222474-A1 | PROCESS FOR PREPARING ATALUREN AND ITS INTERMEDIATES | SCINOPHARM TAIWAN, LTD. (TW) | 2017-12-28 | — | — | WO | disclosed |
| US-20170362192-A1 | PROCESS FOR PREPARING ATALUREN AND ITS INTERMEDIATES | SCINOPHARM TAIWAN, LTD. (TW) | 2017-12-21 | — | — | US | disclosed |
| US-20170362192-A1 | PROCESS FOR PREPARING ATALUREN AND ITS INTERMEDIATES | SCINOPHARM TAIWAN, LTD. (TW) | 2017-12-21 | — | — | US | disclosed |
| EP-3248964-A1 | THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS | PALOBIOFARMA S.L. (ES) | 2017-11-29 | — | — | EP | disclosed |
| US-9809591-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170304275-A1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC THERAPEUTICS, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9737513-B2 | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy | PTC THERAPEUTICS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| EP-3190108-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V Biosciences, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| WO-2017103614-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017103614-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2017-06-22 | — | — | WO | disclosed |
| EP-3178816-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20170119786-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2017-05-04 | — | — | US | disclosed |
| US-9624173-B2 | Heterocyclic modulators of lipid synthesis | 3-V BIOSCIENCES, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9611230-B2 | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| CN-106496210-A | It is used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2017-03-15 | — | — | CN | disclosed |
| CN-106496209-A | It is used as the compound of ATR kinase inhibitors | 沃泰克斯药物股份有限公司 | 2017-03-15 | — | — | CN | disclosed |
| US-20170049752-A1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC THERAPEUTICS, INC. | 2017-02-23 | — | — | US | disclosed |
| CN-106459000-A | NOVEL 3-[(PYRAZOL-5-YL)-HETEROARYL]-BENZAMIDE DERIVATIVES | 拜耳作物科学股份公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-2910551-B1 | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS INC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20170027913-A1 | COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2017-02-02 | — | — | US | disclosed |
| EP-2683244-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES INC (US) | 2017-02-01 | — | — | EP | disclosed |
| CN-104056278-B | 1,2,4-oxadiazole benzoic acid compounds | PTC 治疗公司 | 2017-01-18 | — | — | CN | disclosed |
| WO-2017004964-A1 | PREPARATION METHOD OF 3-[5-(2-FLUOROPHENYL)-1,2,4-OXADIAZOL-3-YL]BENZOIC ACID | 上海适济生物科技有限公司 | 2017-01-12 | — | — | WO | disclosed |
| CN-106316885-A | Preparation method of 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)benzoic acid | 上海适济生物科技有限公司 | 2017-01-11 | — | — | CN | disclosed |
| US-20170002011-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | NORGINE B.V. (NL) | 2017-01-05 | — | — | US | disclosed |
| US-20170002011-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | NORGINE B.V. (NL) | 2017-01-05 | — | — | US | disclosed |
| US-9522137-B2 | Methods for dosing an orally active 1,2,4-Oxadiazole for nonsense mutation suppression therapy | PTC THERAPEUTICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| EP-3103800-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| CN-102300862-B | Compounds useful as inhibitors of ATR kinase | 沃泰克斯药物股份有限公司 | 2016-11-23 | — | — | CN | disclosed |
| EP-3087074-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | Norgine BV (NL) | 2016-11-02 | — | — | EP | disclosed |
| US-9474743-B2 | Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160280668-A1 | NOVEL COMPOUNDS FOR COMBATING ARTHROPODS | ELANCO ANIMAL HEALTH GMBH (DE) | 2016-09-29 | — | — | US | disclosed |
| EP-3067053-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| CN-103958487-B | Benzoic acid derivative as EIF4E inhibitor | 霍夫曼-拉罗奇有限公司 | 2016-07-13 | — | — | CN | disclosed |
| WO-2016073545-A1 | PHENYLOXADIAZOLE BENZOIC ACIDS | CONCERT PHARMACEUTICALS, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20160101087-A1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC THERAPEUTICS, INC. | 2016-04-14 | — | — | US | disclosed |
| EP-1815206-B1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS INC (US) | 2016-04-06 | — | — | EP | disclosed |
| CN-105461650-A | Oxdiazole compound solvate and preparation method thereof | HANGZHOU PUSHAI PHARMACEUTICAL TECH CO LTD | 2016-04-06 | — | — | CN | disclosed |
| US-20160081988-A1 | COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9226919-B2 | Methods for dosing an orally active 1,2,4-oxadiazole | PTC THERAPEUTICS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9205088-B2 | Compositions of 1,2,4-oxadiazol benzoic acid compounds and methods for their use | PTC THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2939674-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150274674-A1 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC THERAPEUTICS, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2460520-B1 | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy | PTC THERAPEUTICS INC (US) | 2015-09-30 | — | — | EP | disclosed |
| US-9145354-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| EP-2910551-A1 | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC Therapeutics, Inc. (US) | 2015-08-26 | — | — | EP | disclosed |
| WO-2015097122-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | NORGINE B.V. (NL) | 2015-07-02 | — | — | WO | disclosed |
| WO-2015097122-A1 | BENZENE SULFONAMIDES AS CCR9 INHIBITORS | NORGINE B.V. (NL) | 2015-07-02 | — | — | WO | disclosed |
| US-9051342-B2 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases | PTC THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20150148346-A1 | COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND METHODS FOR THEIR USE | PTC THERAPEUTICS INC. (US) | 2015-05-28 | — | — | US | disclosed |
| CN-101553226-B | Method of nonsense mutation suppression therapy with orally active 1,2, 4-oxadiazoles | PTC THERAPEUTICS INC | 2015-05-13 | — | — | CN | disclosed |
| CN-104513213-A | Fxr agonist | KBP BIOSCIENCES CO LTD | 2015-04-15 | — | — | CN | disclosed |
| CN-103211766-B | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy | PTC THERAPEUTICS INC | 2015-03-11 | — | — | CN | disclosed |
| US-8975287-B2 | Methods for using 1,2,4-Oxadiazole benzoic acid compounds | PTC THERAPEUTICS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2073805-B1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC THERAPEUTICS INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20150051199-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-19 | — | — | US | disclosed |
| CN-104292180-A | Preparation method of oxadiazole derivative | Hunan huateng pharmaceutical co ltd | 2015-01-21 | — | — | CN | disclosed |
| CN-104292180-A | Preparation method of oxadiazole derivative | Hunan huateng pharmaceutical co ltd | 2015-01-21 | — | — | CN | disclosed |
| CN-101535284-B | Processes for the preparation of 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS INC | 2014-12-10 | — | — | CN | disclosed |
| EP-1618098-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20140301978-A1 | METHODS FOR USING 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS INC. (US) | 2014-10-09 | — | — | US | disclosed |
| CN-102448928-B | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2014-10-01 | — | — | CN | disclosed |
| CN-101970420-B | Oxadiazole derivatives | MERCK SERONO SA | 2014-09-24 | — | — | CN | disclosed |
| CN-104056278-A | 1,2,4-oxadiazole benzoic acid compounds | PTC THERAPEUTICS INC | 2014-09-24 | — | — | CN | disclosed |
| EP-2773615-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2014-09-10 | — | — | EP | disclosed |
| CN-104039766-A | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD | 2014-09-10 | — | — | CN | disclosed |
| US-20140221436-A1 | COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8796322-B2 | Methods for using 1,2,4-oxadiazole benzoic acid compounds | PTC THERAPEUTICS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| CN-1802360-B | 1,2, 4-oxadiazole benzoic acid compounds | PTC THERAPEUTICS INC | 2014-05-07 | — | — | CN | disclosed |
| US-8716321-B2 | Methods for dosing an orally active 1,2,4-oxadiazole | PTC THERAPEUTICS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| CN-103720688-A | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy | PTC THERAPEUTICS INC | 2014-04-16 | — | — | CN | disclosed |
| CN-103664432-A | Preparation technology of organic cyanide | BANNERBIO NUTRACEUTICALS INC | 2014-03-26 | — | — | CN | disclosed |
| US-20130289007-A1 | METHODS FOR USING 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS INC. (US) | 2013-10-31 | — | — | US | disclosed |
| EP-1656345-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-10-16 | — | — | EP | disclosed |
| CN-103211766-A | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy | PTC THERAPEUTICS INC | 2013-07-24 | — | — | CN | disclosed |
| US-8486982-B2 | 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| WO-2013064543-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| CN-101891649-B | Novel 3-cyano methyl benzoate preparing method | JINGZHOU TENGFEI CHEMICALS CO LTD | 2013-05-08 | — | — | CN | disclosed |
| CN-101891649-B | Novel 3-cyano methyl benzoate preparing method | JINGZHOU TENGFEI CHEMICALS CO LTD | 2013-05-08 | — | — | CN | disclosed |
| CN-101891649-B | Novel 3-cyano methyl benzoate preparing method | JINGZHOU TENGFEI CHEMICALS CO LTD | 2013-05-08 | — | — | CN | disclosed |
| EP-2099788-B1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER IP GMBH (DE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2099788-B1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER IP GMBH (DE) | 2013-03-06 | — | — | EP | disclosed |
| US-8367841-B2 | Processes for the preparation of 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367841-B2 | Processes for the preparation of 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367841-B2 | Processes for the preparation of 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2059513-B1 | Process for the preparation of 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS INC (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2059513-B1 | Process for the preparation of 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS INC (US) | 2013-01-23 | — | — | EP | disclosed |
| US-8304412-B2 | Cyclically substituted 3,5-dicyano-2-thiopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304412-B2 | Cyclically substituted 3,5-dicyano-2-thiopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20120277234-A1 | 1,2,4-OXADIAZOLE BENZOIC ACIDS | PTC THERAPEUTICS, INC. | 2012-11-01 | — | — | US | disclosed |
| US-8299105-B2 | 1,2,4-oxadiazole benzoic acid compositions and their use in bioassays | PTC THERAPEUTICS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8227494-B2 | Pharmaceutical compositions of 1,2,4-oxadiazole benzoic acid and their use for the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120178080-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOSITIONS AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| EP-1874306-B1 | COMPOSITIONS OF AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC THERAPEUTICS INC (US) | 2012-07-04 | — | — | EP | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| EP-2460520-A1 | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy | PTC Therapeutics, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| CN-102448928-A | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG | 2012-05-09 | — | — | CN | disclosed |
| US-8163782-B2 | 1,2,4-oxadiazole benzoic acid compositions | PTC THERAPEUTICS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8129540-B2 | Methods for the synthesis of 1,2,4-oxadiazole benzoic acid compounds | PTC THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129540-B2 | Methods for the synthesis of 1,2,4-oxadiazole benzoic acid compounds | PTC THERAPEUTICS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2402323-A2 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402002-A1 | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy | PTC Therapeutics, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| EP-2387995-A1 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC Therapeutics, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-D646941-S1 | Scissors | B.H.P. Industries Co., Ltd. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-8017636-B2 | 1,2,4-Oxadiazole benzoic acid compositions and their use in bioassays | PTC THERAPEUTICS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| EP-2363129-A1 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| CN-1871215-B | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO | 2011-06-08 | — | — | CN | disclosed |
| EP-2316452-A1 | Pyrrol derivatives, uses thereof | PTC Therapeutics, Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2311830-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311455-A1 | Compounds for nonsense suppression, and methods for their use | PTC Therapeutics, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2301536-A1 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2301538-A1 | Compounds for nonsense suppression, and methods for their use | PTC Therapeutics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-1277738-B1 | CONDENSED HETEROARYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| CN-101970420-A | Oxadiazole derivatives | MERCK SERONO SA | 2011-02-09 | — | — | CN | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| CN-101891649-A | Novel 3-cyano methyl benzoate preparing method | JINGZHOU TENGFEI CHEMICALS CO LTD | 2010-11-24 | — | — | CN | disclosed |
| CN-101891649-A | Novel 3-cyano methyl benzoate preparing method | JINGZHOU TENGFEI CHEMICALS CO LTD | 2010-11-24 | — | — | CN | disclosed |
| CN-101891649-A | Novel 3-cyano methyl benzoate preparing method | JINGZHOU TENGFEI CHEMICALS CO LTD | 2010-11-24 | — | — | CN | disclosed |
| EP-2250165-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | Merck Serono S.A. (CH) | 2010-11-17 | — | — | EP | disclosed |
| US-7829571-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| EP-1723144-B1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-20100216851-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOSITIONS AND THEIR USE IN BIOASSAYS | PTC THERAPEUTICS, INC. | 2010-08-26 | — | — | US | disclosed |
| US-7772259-B2 | E.g., 3-[5-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100168109-A1 | PHARMACEUTICAL COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID AND THEIR USE FOR THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100121070-A1 | METHODS FOR THE SYNTHESIS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-7696238-B2 | Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics | GRUENENTHAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-7683082-B2 | 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in full length protein; genetic disorders; testing whether a compound increases activity of a protein encoded by an mRNA that contains a premature stop codon | PTC THERAPEUTICS, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7678922-B2 | Processes for the preparation of 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678922-B2 | Processes for the preparation of 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20100063297-A1 | PROCESSES FOR THE PREPARATION OF 1,2,4-OXADIAZOLE BENZOIC ACIDS | PTC THERAPEUTICS, INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100063297-A1 | PROCESSES FOR THE PREPARATION OF 1,2,4-OXADIAZOLE BENZOIC ACIDS | PTC THERAPEUTICS, INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100063297-A1 | PROCESSES FOR THE PREPARATION OF 1,2,4-OXADIAZOLE BENZOIC ACIDS | PTC THERAPEUTICS, INC. | 2010-03-11 | — | — | US | disclosed |
| US-7659267-B2 | 1,3-Benzothiazinone derivatives, process for producing the same use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20100022544-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022544-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| US-7645776-B2 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1959951-B1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PCT THERAPEUTICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| CN-101553226-A | Method of nonsense mutation suppression therapy with orally active 1,2, 4-oxadiazoles | PTC THERAPEUTICS INC (US) | 2009-10-07 | — | — | CN | disclosed |
| CN-101553486-A | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators | NEUROSEARCH AS (DK) | 2009-10-07 | — | — | CN | disclosed |
| EP-2099788-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-16 | — | — | EP | disclosed |
| CN-101535284-A | Processes for the preparation of 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS INC (US) | 2009-09-16 | — | — | CN | disclosed |
| US-7585881-B2 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| CN-101505739-A | Method for producing functional proteins from DNA with nonsense mutations and treatment of related diseases | PTC THERAPEUTICS INC (US) | 2009-08-12 | — | — | CN | disclosed |
| WO-2009080663-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-07-02 | — | — | WO | disclosed |
| EP-2073805-A1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC Therapeutics, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090149513-A1 | Compositions of an Orally Active 1,2,4-Oxadiazole for Nonsense Mutation Suppression Therapy | PTC THERAPEUTICS, INC. | 2009-06-11 | — | — | US | disclosed |
| EP-2059513-A1 | PROCESSES FOR THE PREPARATION OF 1,2,4-OXADIAZOLE BENZOIC ACIDS | PTC Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-14 | — | — | US | disclosed |
| EP-1814846-B1 | 11BETA-HSD1 INHIBITORS | EVOTEC AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| US-20090069323-A1 | 11beta-hsdi inhibitors | EVOTEC AG (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069323-A1 | 11beta-hsdi inhibitors | EVOTEC AG (DE) | 2009-03-12 | — | — | US | disclosed |
| US-7482335-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| EP-2007365-A2 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC Therapeutics, Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7456200-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-11-25 | — | — | US | disclosed |
| US-20080280869-A1 | Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080269191-A1 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269191-A1 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7419991-B2 | Treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1959951-A1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | F. Hoffmann-la Roche AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20080194742-A1 | Method for Undistorted Pigmentation of Partially Crystalline Plastics | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| EP-1618098-A4 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PCT THERAPEUTICS INC (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20080139818-A1 | Processes for the preparation of 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139818-A1 | Processes for the preparation of 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008064788-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008064788-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-05 | — | — | WO | disclosed |
| CN-101193632-A | Orally active 1,2, 4-oxadiazole compositions for nonsense mutation suppression therapy | PTC THERAPEUTICS INC (US) | 2008-06-04 | — | — | CN | disclosed |
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20080114039-A1 | Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy | PTC THERAPEUTICS, INC. | 2008-05-15 | — | — | US | disclosed |
| WO-2008045566-A1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008030570-A1 | PROCESSES FOR THE PREPARATION OF 1,2,4-OXADIAZOLE BENZOIC ACIDS | PTC THERAPEUTICS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030570-A1 | PROCESSES FOR THE PREPARATION OF 1,2,4-OXADIAZOLE BENZOIC ACIDS | PTC THERAPEUTICS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080015204-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| EP-1874306-A1 | COMPOSITIONS OF AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC Therapeutics, Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070293545-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-7304080-B2 | E.g., 3-[5-(2-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| CN-101076703-A | Compounds for nonsense inhibition and methods of use thereof | PTC THERAPEUTICS INC (US) | 2007-11-21 | — | — | CN | disclosed |
| CN-101076332-A | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC THERAPEUTICS INC (US) | 2007-11-21 | — | — | CN | disclosed |
| CN-100345830-C | Condensed heteroaryl derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 2007-10-31 | — | — | CN | disclosed |
| WO-2007117438-A2 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-1814846-A1 | 11BETA-HSD1 INHIBITORS | Evotec AG (DE) | 2007-08-08 | — | — | EP | disclosed |
| EP-1815206-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070179188-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | US | disclosed |
| EP-1812071-A2 | COMPOUNDS FOR NONSENSE SUPPRESSION, USE OF THESE COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC Therapeutics, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20070161687-A1 | 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in full length protein; genetic disorders; testing whether a compound increases activity of a protein encoded by an mRNA that contains a premature stop codon | PTC THERAPEUTICS, INC. | 2007-07-12 | — | — | US | disclosed |
| EP-1799207-A2 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC Therapeutics, Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007063012-A1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | US | disclosed |
| EP-1656138-A4 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7202262-B2 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders | PTC THERAPEUTICS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CARTER PEROY H | 2007-02-08 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7163937-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| US-7151098-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-12-19 | — | — | US | disclosed |
| EP-1270577-B1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-12-06 | — | — | EP | disclosed |
| CN-1871215-A | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2006-11-29 | — | — | CN | disclosed |
| EP-1723144-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006110483-A1 | COMPOSITIONS OF AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | PTC THERAPEUTICS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| CN-1268626-C | Dihydro-benzo(b)(1,4)diazepin-2-one derivatives as mglur2 antagonists I | HOFFMANN LA ROCHE (CH) | 2006-08-09 | — | — | CN | disclosed |
| CN-1264825-C | Dihydro-benzo [ b ] [1,4] diazepin * -2-one derivatives as mGluR2 antagonists II | HOFFMANN LA ROCHE (CH) | 2006-07-19 | — | — | CN | disclosed |
| CN-1802360-A | 1,2, 4-oxadiazole benzoic acid compounds | PTC THERAPEUTICS INC (US) | 2006-07-12 | — | — | CN | disclosed |
| US-20060148864-A1 | Treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060148863-A1 | E.g., 3-[5-(2-Chloro-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060148791-A1 | Glutamate receptor antagonists | ADAM GEO | 2006-07-06 | — | — | US | disclosed |
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1656345-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1656138-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006048330-A1 | 11ΒΕΤΑ-HSD1 INHIBITORS | EVOTEC AG (DE) | 2006-05-11 | — | — | WO | disclosed |
| EP-1655283-A1 | 11beta-HSD1 Inhibitors | Evotec OAI AG (DE) | 2006-05-10 | — | — | EP | disclosed |
| US-7037915-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| WO-2006044502-A2 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006044503-A2 | COMPOUNDS FOR NONSENSE SUPPRESSION, USE OF THESE COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006044456-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-7018998-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20060058321-A1 | Fused heterolaryl derivatives | HAYAKAWA MASAHIKO | 2006-03-16 | — | — | US | disclosed |
| US-20060052371-A1 | 1,3-Benzothiazinone derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-09 | — | — | US | disclosed |
| US-20060035943-A1 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. | 2006-02-16 | — | — | US | disclosed |
| WO-2006014185-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-02-09 | — | — | WO | disclosed |
| US-6992096-B2 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| EP-1618098-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PCT Therapeutics Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
| US-6962933-B1 | Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-08 | — | — | US | disclosed |
| US-6960578-B2 | Glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050234048-A1 | Glutamate receptor antagonists | ADAM GEO | 2005-10-20 | — | — | US | disclosed |
| EP-1583965-A1 | METHOD FOR DETERMINING MOLECULAR AFFINITIES FOR HUMAN SERUM ALBUMIN | Pharmacia & Upjohn Company LLC (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1568697-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-6924292-B2 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20050164973-A1 | E.g., 3-[5-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay | PCT THERAPEUTICS, INC. | 2005-07-28 | — | — | US | disclosed |
| EP-1379511-B1 | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | HOFFMANN LA ROCHE (CH) | 2005-07-20 | — | — | EP | disclosed |
| US-20050150764-A1 | Tetrahydropyridazine derivatives and their use as pesticides | MAURER FRITZ (DE) | 2005-07-14 | — | — | US | disclosed |
| CN-1629145-A | Condensed heteroaryl derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 2005-06-22 | — | — | CN | disclosed |
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | disclosed |
| EP-1529045-A2 | NEW COMPOUNDS | Astra Zeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| CN-1199954-C | Benzodiazepine derivatives | HOFFMANN LA ROCHE (CH) | 2005-05-04 | — | — | CN | disclosed |
| CN-1195522-C | Benzodiazepine derivatives usable as parental metabolic glutamate receptor antagonist | HOFFMANN LA ROCHE (CH) | 2005-04-06 | — | — | CN | disclosed |
| EP-1514866-A1 | Process for producing cyanobenzoic acid derivatives | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2005020899-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| WO-2005021500-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| EP-1508567-A2 | Process for producing cyanobenzoic acid derivatives | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2005-02-23 | — | — | EP | disclosed |
| EP-1379522-B1 | DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | HOFFMANN LA ROCHE (CH) | 2005-01-26 | — | — | EP | disclosed |
| CN-1186324-C | Fused heteroaryl derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 2005-01-26 | — | — | CN | disclosed |
| US-20050014771-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2005-01-20 | — | — | US | disclosed |
| US-20050003449-A1 | Method for determining molecular affinities for human serum albumin | PHARMACIA & UPJOHN COMPANY | 2005-01-06 | — | — | US | disclosed |
| US-6838457-B2 | Fused heteroaryl derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| WO-2004091502-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
| CN-1535270-A | Tetrahydropyridazine derivatives and their use as pesticides | �ݶ�ũ�����ѧ�ɷݹ�˾ | 2004-10-06 | — | — | CN | disclosed |
| CN-1535266-A | Dihydro-benzo [b][1,4] diazepin-2-one derivatives as mglur 2 antagonists II | - | 2004-10-06 | — | — | CN | disclosed |
| CN-1522252-A | Dihydro-benzo(b)(1,4)diazepin-2-one derivatives as mglur2 antagonists I | - | 2004-08-18 | — | — | CN | disclosed |
| US-20040152699-A1 | Compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| US-6770641-B2 | Fused heteroaryl derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| WO-2004063749-A1 | METHOD FOR DETERMINING MOLECULAR AFFINITIES FOR HUMAN SERUM ALBUMIN | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1224175-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2004-03-17 | — | — | EP | disclosed |
| WO-2004018414-A2 | ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004014881-A2 | '1,2,4'OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRA ZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
| US-20040009978-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1379522-A1 | DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| EP-1379511-A1 | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-20030236271-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2003-12-25 | — | — | US | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1224174-B1 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-6608056-B1 | Phosphatidylinositol 3-kinase inhibitors and carcinostatic agents | YAMANOUCHI PHARMACEUTICAL CO., LTD (JP) | 2003-08-19 | — | — | US | disclosed |
| US-6608053-B2 | Phosphatidylinositol 3-kinase (PI3K) inhibitors/anticancer agents such as N-(2-(3-benzenesulfonylaminophenyl)-4-morphoniloquinazolin-6-yl)acetamide | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| CN-1426398-A | Fused heteroaryl derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 2003-06-25 | — | — | CN | disclosed |
| US-20030092677-A1 | Glutamate receptor antagonists | ADAM GEO (DE) | 2003-05-15 | — | — | US | disclosed |
| US-6548495-B2 | Metabotropic glutamate receptor agonist for treatment or prevention of acute and/or chronic neurological disorders | HOFFMANN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| CN-1105116-C | Thienopyrimidines with PDE V-inhibiting action | MERCK PATENT GMBH (DE) | 2003-04-09 | — | — | CN | disclosed |
| US-6544985-B2 | For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits | HOFFMAN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| EP-1277738-A1 | CONDENSED HETEROARYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-6509328-B1 | Metabotropic glutamate receptor antagonists and accordingly are useful for the treatment of a range of neurological disorders, including psychosis, schizophrenia, Alzheimer's and others | HOFFMANN-LA ROCHE INC. | 2003-01-21 | — | — | US | disclosed |
| EP-1270577-A1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2002-12-19 | — | — | US | disclosed |
| CN-1379764-A | Benzodiazepine derivatives | HOFFMANN LA ROCHE (CH) | 2002-11-13 | — | — | CN | disclosed |
| CN-1379765-A | Benzodiazepine derivatives usable as parental metabolic glutamate receptor antagonist | HOFFMANN LA ROCHE (CH) | 2002-11-13 | — | — | CN | disclosed |
| WO-2002083652-A1 | DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083665-A1 | DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-24 | — | — | WO | disclosed |
| US-20020151544-A1 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2002-10-17 | — | — | US | disclosed |
| US-6433211-B1 | SELECTIVITY HYDRATION OF AROMATIC DINITRILES | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2002-08-13 | — | — | US | disclosed |
| EP-1224175-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| EP-1224174-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| US-6407094-B1 | 4-5-DIDEHYDRO-1,5-BENZODIAZEPIN-2-ONE DERIVATIVES; PSYCHOLOGICAL, NERVOUS SYSTEM, AND BRAIN DISORDERS; COGNITION ACTIVATORS; ALZHEIMER*S DISEASE, SCHIZOPHRENIA | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | disclosed |
| EP-1205478-A1 | p38MAP KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-0775133-B1 | NAPHTHALENE AMIDES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | MENARINI LAB (ES) | 2001-05-30 | — | — | EP | disclosed |
| WO-2001029012-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029011-A2 | BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| US-6130223-A | Thienopyrimidine with phosphodiesterase V inhibiting effect | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-10-10 | — | — | US | disclosed |
| EP-0989115-A2 | Process for producing cyanobenzoic acid derivatives | Showa Denko Kabushiki Kaisha (JP) | 2000-03-29 | — | — | EP | disclosed |
| CN-1240450-A | Thienopyrimidine with phosphodiesterase V inhibiting effect | MERCK PATENT GMBH (DE) | 2000-01-05 | — | — | CN | disclosed |
| EP-0784612-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
| EP-0775133-A1 | NAPHTHALENE AMIDES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
| WO-1996004267-A1 | NAPHTHALENE AMIDES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
| WO-1994007872-A1 | PROCESS FOR THE PREPARATION OF TETRAZOLES | ABBOTT LABORATORIES (US) | 1994-04-14 | — | — | WO | disclosed |
| US-5284954-A | Process for the preparation of tetrazoles | ABBOTT LABORATORIES (US) | 1994-02-08 | — | — | US | disclosed |
| EP-0577743-A1 | PHOTODEFINABLE INTERLEVEL DIELECTRICS | AlliedSignal Inc. (US) | 1994-01-12 | — | — | EP | disclosed |
| EP-0563247-A1 | PHOTODEFINABLE INTERLEVEL DIELECTRICS | AlliedSignal Inc. (US) | 1993-10-06 | — | — | EP | disclosed |
| US-5216158-A | Oxadiazole compounds containing 4,6-bis-trichloromethyl-S-triazin-2-yl groups, process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-06-01 | — | — | US | disclosed |
| US-5185209-A | Electronic interconnect structure; pattern from prepolymer which is an ether of the oligomeric condensation product of a dihydric phenol and formaldehyde | ALLIED-SIGNAL INC. (US) | 1993-02-09 | — | — | US | disclosed |
| US-5185210-A | Electronic interconnect structure; pattern from mixture of prepolymer which are the ethers of the oligomeric condensation product of (a) dihydric phenol and formaldehyde and (b) dialdehyde and phenol | ALLIED-SIGNAL INC. (US) | 1993-02-09 | — | — | US | disclosed |
| WO-1992017820-A1 | PHOTODEFINABLE INTERLEVEL DIELECTRICS | ALLIED-SIGNAL INC. (US) | 1992-10-15 | — | — | WO | disclosed |
| US-5139880-A | Photoresists comprising oligomers of a fluorinated dihydric phenol/formaldehyde and a dialdehyde/phenol; microcircuits; hardness; adhesion; shrinkage and chemical resistance | ALLIED-SIGNAL INC. (US) | 1992-08-18 | — | — | US | disclosed |
| WO-1992011580-A1 | PHOTODEFINABLE INTERLEVEL DIELECTRICS | ALLIED-SIGNAL INC. (US) | 1992-07-09 | — | — | WO | disclosed |
| WO-1992011578-A1 | PHOTODEFINABLE INTERLEVEL DIELECTRICS | ALLIED-SIGNAL INC. (US) | 1992-07-09 | — | — | WO | disclosed |
| US-5120569-A | Prepolymer of ether of dihydric phenol and formaldehyde | ALLIED-SIGNAL INC. (US) | 1992-06-09 | — | — | US | disclosed |
| US-5114741-A | Ethers of reaction product of a dicyclopentadiene and a phenol and of a dialdehyde and a phenol | ALLIED-SIGNAL INC. (US) | 1992-05-19 | — | — | US | disclosed |
| US-5085886-A | Dielectric polymer is formed on substrate from the ether reaction product of dicyclopentadiene and a phenol | ALLIED-SIGNAL INC. (US) | 1992-02-04 | — | — | US | disclosed |
| US-5064959-A | Photoinitiators | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-11-12 | — | — | US | disclosed |
| US-5064959-A | Photoinitiators | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | MRGPRX4 56/4885GSK3B 4278/4885CYP11B1 308/4885 |
| US-20050113450-A1 | Antibacterial agents | CLPP, SPOUT1, SAMHD1 | MRGPRX4 3514/4885GSK3B 4601/4885CYP11B1 4848/4885 |
| US-11497736-B2 | Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease | SMN1; SMN2, UPF1, VHL | MRGPRX4 4164/4885GSK3B 3924/4885CYP11B1 208/4885 |
| US-20040152699-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | MRGPRX4 616/4885GSK3B 2690/4885CYP11B1 3/4885 |
| US-20030092677-A1 | Glutamate receptor antagonists | GRM1, GRM3, GRM2 | MRGPRX4 217/4885GSK3B 4288/4885CYP11B1 3403/4885 |
| US-20240351984-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | MRGPRX4 4658/4885GSK3B 419/4885CYP11B1 3504/4885 |
| US-20180140583-A1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | UPF1, VHL, SLC25A21 | MRGPRX4 4313/4885GSK3B 4427/4885CYP11B1 573/4885 |
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | MRGPRX4 307/4885GSK3B 2834/4885CYP11B1 2126/4885 |
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | GRM5, GRIK5, GRM1 | MRGPRX4 244/4885GSK3B 3396/4885CYP11B1 2435/4885 |
| US-20180079746-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | MRGPRX4 4157/4885GSK3B 2068/4885CYP11B1 181/4885 |
| US-20030236271-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | MRGPRX4 4104/4885GSK3B 169/4885CYP11B1 2585/4885 |
| US-20170049752-A1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | UPF1, VHL, SLC25A21 | MRGPRX4 4313/4885GSK3B 4427/4885CYP11B1 573/4885 |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | OXA1L, RO60, PDCD11 | MRGPRX4 207/4885GSK3B 320/4885CYP11B1 425/4885 |
| US-20210380562-A1 | Novel Compounds | USP30, USP20, USP10 | MRGPRX4 2992/4885GSK3B 2289/4885CYP11B1 570/4885 |
| US-20120277234-A1 | 1,2,4-OXADIAZOLE BENZOIC ACIDS | UPF1, RIOX2, RPL35A | MRGPRX4 4029/4885GSK3B 3614/4885CYP11B1 871/4885 |
| US-20160101087-A1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | UPF1, VHL, SLC25A21 | MRGPRX4 4313/4885GSK3B 4427/4885CYP11B1 573/4885 |
| US-20040009978-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | MRGPRX4 4104/4885GSK3B 169/4885CYP11B1 2585/4885 |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | UPF1, DNAJC10, RNGTT | MRGPRX4 4744/4885GSK3B 4692/4885CYP11B1 3560/4885 |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | MRGPRX4 4104/4885GSK3B 169/4885CYP11B1 2585/4885 |
| US-20100168109-A1 | PHARMACEUTICAL COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID AND THEIR USE FOR THE TREATMENT OF DISEASE | UPF1, RIOX2, PABPC1 | MRGPRX4 3392/4885GSK3B 3533/4885CYP11B1 463/4885 |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | UPF1, DNAJC10, RNGTT | MRGPRX4 4721/4885GSK3B 4691/4885CYP11B1 3385/4885 |
| US-20080269191-A1 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | UPF1, NSUN2, RNMT | MRGPRX4 4205/4885GSK3B 1671/4885CYP11B1 2684/4885 |
| US-11130748-B2 | Compounds | USP30, USP20, USP10 | MRGPRX4 3056/4885GSK3B 1991/4885CYP11B1 475/4885 |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | MRGPRX4 117/4885GSK3B 487/4885CYP11B1 2126/4885 |
| US-20180263963-A1 | MODULATORS OF THE ADENOSINE A3 RECEPTORS | ADORA3, ADORA2A, ADORA1 | MRGPRX4 154/4885GSK3B 2022/4885CYP11B1 851/4885 |
| US-20100022544-A1 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF | QDPR, TPMT, PTGIS | MRGPRX4 1645/4885GSK3B 4713/4885CYP11B1 347/4885 |
| US-20170304275-A1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | UPF1, VHL, SLC25A21 | MRGPRX4 4313/4885GSK3B 4427/4885CYP11B1 573/4885 |
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | ROCK1, ROCK2, TNK2 | MRGPRX4 303/4885GSK3B 523/4885CYP11B1 1372/4885 |
| US-20070179188-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | MRGPRX4 280/4885GSK3B 2681/4885CYP11B1 2067/4885 |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | MRGPRX4 307/4885GSK3B 2834/4885CYP11B1 2126/4885 |
| US-20100121070-A1 | METHODS FOR THE SYNTHESIS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | UPF1, RIOX2, RNMT | MRGPRX4 4048/4885GSK3B 3508/4885CYP11B1 681/4885 |
| US-20250179000-A1 | METABOTROPIC GLUTAMATE RECEPTOR POSITIVE ALLOSTERIC MODULATORS (PAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | MRGPRX4 289/4885GSK3B 2827/4885CYP11B1 4249/4885 |
| US-10034863-B2 | Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease | SMN1; SMN2, UPF1, VHL | MRGPRX4 4164/4885GSK3B 3924/4885CYP11B1 208/4885 |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | MRGPRX4 86/4885GSK3B 4719/4885CYP11B1 904/4885 |
| US-20080139818-A1 | Processes for the preparation of 1,2,4-oxadiazole benzoic acids | UPF1, ABAT, HOGA1 | MRGPRX4 4723/4885GSK3B 4225/4885CYP11B1 121/4885 |
| US-20170119786-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | MRGPRX4 4201/4885GSK3B 1432/4885CYP11B1 210/4885 |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | KCNQ1, KCNQ2, KCNQ3 | MRGPRX4 265/4885GSK3B 2631/4885CYP11B1 2863/4885 |
| US-20090069323-A1 | 11beta-hsdi inhibitors | HSD3B1, HSD3B2, HSD11B1 | MRGPRX4 1361/4885GSK3B 88/4885CYP11B1 15/4885 |
| US-20140301978-A1 | METHODS FOR USING 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | UPF1, RIOX2, RNMT | MRGPRX4 3792/4885GSK3B 3872/4885CYP11B1 761/4885 |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | MRGPRX4 4658/4885GSK3B 419/4885CYP11B1 3504/4885 |
| US-20060058321-A1 | Fused heterolaryl derivatives | PIK3CD, PIK3C2A, PIK3R1 | MRGPRX4 4255/4885GSK3B 144/4885CYP11B1 3381/4885 |
| US-20050234048-A1 | Glutamate receptor antagonists | GRM3, GRM1, GRM2 | MRGPRX4 162/4885GSK3B 4274/4885CYP11B1 4060/4885 |
| US-10675272-B2 | Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease | SMN1; SMN2, UPF1, VHL | MRGPRX4 4164/4885GSK3B 3924/4885CYP11B1 208/4885 |
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | MRGPRX4 4141/4885GSK3B 3468/4885CYP11B1 3210/4885 |
| US-20210038572-A1 | METHODS FOR DOSING AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENSE MUTATION SUPPRESSION THERAPY | UPF1, VHL, SLC25A21 | MRGPRX4 4313/4885GSK3B 4427/4885CYP11B1 573/4885 |
| US-20230218587-A1 | COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE | SMN1; SMN2, UPF1, VHL | MRGPRX4 4164/4885GSK3B 3924/4885CYP11B1 208/4885 |
| US-20150148346-A1 | COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND METHODS FOR THEIR USE | UPF1, RIOX2, RNMT | MRGPRX4 4066/4885GSK3B 3312/4885CYP11B1 853/4885 |
| US-11034690-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, SCD | MRGPRX4 4201/4885GSK3B 1432/4885CYP11B1 210/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | MRGPRX4 4104/4885GSK3B 169/4885CYP11B1 2585/4885 |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | MRGPRX4 4201/4885GSK3B 1432/4885CYP11B1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.